Description

PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic (IVD) solutions, encompassing both diagnostic products and specialized platform services. The company's primary offerings include comprehensive multiplex kits designed to detect antibodies to Human Immunodeficiency Virus (HIV) types 1 and 2, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human T-lymphotropic Virus (HTLV) types 1 and 2. These kits also identify specific antigens such as HIV p24, HCV core, and HBV surface markers in human serum or plasma samples. In addition to these, PCL markets Ai, a rapid diagnostic test kit capable of typing influenza A and B strains; Cancer6, a screening kit for multiple tumor biomarkers; and the sciLINER LATERAL FLOW DISPENSER, an advanced dispensing device for membrane materials featuring active visual drop volume control. Beyond its product portfolio, PCL offers valuable platform services. These include a sol-gel spotting service, which immobilizes client-specified materials using the proprietary SolB reagent, and an SG ID service, providing customers with identified molecules of interest securely immobilized within the SolB reagent. PCL, Inc. is headquartered in Seoul, South Korea.